Deteriorating Atrioventricular Block in COVID-19 Suspected Patient after Receiving Initial Dose of Azythromycin and Hydroxychloroquine

Billy Aditya Pratama; Afik Maulana Rachman; Vita Yanti Anggraeni; Erika Maharani; Ika Trisnawati; Bambang Sigit Riyanto; Anggoro Budi Hartopo

doi:10.20944/preprints202005.0190.v1

How to cite: Pratama, B.A.; Rachman, A.M.; Anggraeni, V.Y.; Maharani, E.; Trisnawati, I.; Riyanto, B.S.; Hartopo, A.B. Deteriorating Atrioventricular Block in COVID-19 Suspected Patient after Receiving Initial Dose of Azythromycin and Hydroxychloroquine. Preprints 2020, 2020050190. https://doi.org/10.20944/preprints202005.0190.v1 Pratama, B.A.; Rachman, A.M.; Anggraeni, V.Y.; Maharani, E.; Trisnawati, I.; Riyanto, B.S.; Hartopo, A.B. Deteriorating Atrioventricular Block in COVID-19 Suspected Patient after Receiving Initial Dose of Azythromycin and Hydroxychloroquine. Preprints 2020, 2020050190. https://doi.org/10.20944/preprints202005.0190.v1

Abstract

Coronavirus 2019 (COVID-19) is an infectious disease that is becoming a pandemic. Hydroxychloroquine in combination with azythromycin are among drugs currently in use to eradicate COVID-19. Despite concerns due to its potential cardiac toxicity, hydroxychloroquine is widely accepted in mild and moderate COVID-19 pneumonia. In this case report, we report a case of a young Indonesian adult male with suspected COVID-19 pneumonia who received hydroxychloroquine and azythromycin therapies and during 24 hour experienced deterioration of atrioventricular block.

Keywords

Subject

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Deteriorating Atrioventricular Block in COVID-19 Suspected Patient after Receiving Initial Dose of Azythromycin and Hydroxychloroquine

Abstract

Keywords

Subject

Comments (0)